ResMed, Inc.

Equities

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 01:30:01 11/09/2024 am IST			5-day change	1st Jan Change
252.86 ^USD	+1.32%		+3.25%	+46.99%

09:26am	ResMed Insider Sold Shares Worth $3,646,950, According to a Recent SEC Filing	MT
06/09	Resmed Insider Sold Shares Worth $479,800, According to a Recent SEC Filing	MT

ResMed Seeks Acquisitions

August 02, 2024 at 02:00 am IST

ResMed Inc. (NYSE:RMD) is looking for acquisitions. During the company's fourth quarter of fiscal year 2024 earnings conference call, Brett Sandercock, Chief Financial Officer said that ?Going forward, we plan to continue to reinvest in growth through R&D, deploy further capital for tuck-in acquisitions and continue with our share buyback program?.

Latest news about ResMed, Inc.

ResMed Insider Sold Shares Worth $3,646,950, According to a Recent SEC Filing	12:56pm	MT
Resmed Insider Sold Shares Worth $479,800, According to a Recent SEC Filing	07/09	MT
Transcript : ResMed Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 10:00 AM	04/09
Needham Downgrades ResMed to Hold From Buy	04/09	MT
ResMed Elects Christopher DelOrefice to the Board	16/08	CI
Resmed Insider Sold Shares Worth $2,166,000, According to a Recent SEC Filing	14/08	MT
Resmed Insider Sold Shares Worth $3,145,905, According to a Recent SEC Filing	09/08	MT
Resmed Insider Sold Shares Worth $10,419,552, According to a Recent SEC Filing	07/08	MT
UBS Adjusts Price Target on ResMed to $225 From $210, Maintains Neutral Rating	05/08	MT
Recession Fears Drag Australian Shares to More than Two-Month Low	05/08	MT
ResMed Shares Hit 52-Week High After Reporting Strong Results on Friday	05/08	MT
RBC Adjusts ResMed's Price Target to $206 From $204, Keeps Sector Perform Rating	02/08	MT
Mizuho Securities Adjusts ResMed Price Target to $230 From $220	02/08	MT
KeyBanc Adjusts Price Target on ResMed to $251 From $238	02/08	MT
Jefferies Adjusts Price Target on ResMed to $200 From $180	02/08	MT
JPMorgan Adjusts Price Target on ResMed to $240 From $225, Maintains Overweight Rating	02/08	MT
Weak US Manufacturing Data Drag Down Australian Shares	02/08	MT
ResMed Fiscal Q4 Revenue Rises 9%, Net Income Up 27%; Lifts Dividend	02/08	MT
ResMed Reports Fiscal Q4 Revenue Up 9% to $1.22 Billion, EPS of $1.98	02/08	MT
ResMed Fiscal Q4 Non-GAAP Earnings, Revenue Rise	02/08	MT
ResMed meets estimates on steady demand for its sleep apnea devices	02/08	RE
ResMed Seeks Acquisitions	02/08	CI
Transcript : ResMed Inc., Q4 2024 Earnings Call, Aug 01, 2024	02/08
Tranche Update on ResMed Inc.'s Equity Buyback Plan announced on February 27, 2014.	02/08	CI
ResMed Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2024	02/08	CI

Chart ResMed, Inc.

Duration

Period

More charts

Company Profile

ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows: - medical devices (50.4%); - masks (37.9%); - software as a service (11.7%). At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia. The United States accounts for 61.4% of net sales.

Employees

9,980

Sector

Advanced Medical Equipment & Technology

Calendar

30/09/2024 - Investor Day

Related indices

S&P 500 , S&P/ASX 200

More about the company